Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melike Ozcelik

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancers|September 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Taha Koray Sahin, et al.
Medicine|November 14, 2023
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from TurkeyArif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, et al.
BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancers|September 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Taha Koray Sahin, et al.
Medicine|November 14, 2023
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from TurkeyArif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, et al.
BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.
Pageof 4